You are here

Funding

Detection of HIV for Self-Testing (R61/R33) - Expiration Date: December 7, 2019
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support bi-phasic developmental, discovery-driven, or hypothesis-driven research focused on innovative strategies to detect HIV either within the first two weeks of infection or to monitor viral rebound after stopping or developing resistance to antiretroviral therapy. Applications should propose simple diagnostic tools that would be feasible for a self-testing platform to allow untrained individuals to detect HIV. Interdisciplinary collaborations that include biomedical, physical, and behavioral sciences are highly encouraged.    
  • Open Date: November 6, 2017
  • Amount of Award: NIAID intends to commit $2,640,000 in FY 2018 to fund 3-6 awards. NIMH intends to commit $300,000 total cost in FY 2018.  Future year amounts will depend on annual appropriations. 
  • Due Date: December 6, 2017, December 6, 2018, and December 6, 2019 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
    December 6, 2017, December 6, 2018, and December 6, 2019, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-17-471.html
  • End Date: December 7, 2019
HIV Research Grant for African-American and Latino/a Medical Students - RAMP Application 2020-2021 Now Live - Deadline: January 6, 2020

HIV Vaccine Research Grants for Medical Students
Seeking African American/Black and Latinx medical students interested in HIV vaccine research

The HIV Vaccine Trials Network, in collaboration with the National Institute of Mental Health, the National Institute of Allergy and Infectious Diseases and the Bill & Melinda Gates Foundation, is investing in a young generation of HIV prevention researchers by providing African-American and Latinx medical students with opportunities to conduct independent research while receiving mentoring, project and salary funding, training, and professional development opportunities. The complete Request for Applications can be found at http://www.hvtn.org/ramp

Grant recipients will be mentored by HVTN-affiliated investigators while conducting research projects in areas of basic, clinical, behavioral and social science. Projects will be:

Short-Term Projects: 2-3 months

  • Timed with a summer break or fourth year research elective
  • Travel to an HIV Vaccine Trials Unit abroad
  • Attend and present at an HVTN Conference
  • Maximum award of $20,000

Project Options

Scholars will have the opportunity to apply to a research project of their interest. Project summaries for the 2020-2021 Cycle will be posted the week of December 2nd, 2019 at the following link: http://www.hvtn.org/ramp.

To see projects of our current and former scholars, check out their profiles.

Application Materials
If you are interested in applying, visit http://www.hvtn.org/ramp, review the Request For Applications (RFA) and application materials. Carefully read the Request for Applications before applying. Applications are due via the web-based application form by 5:00 pm PST on January 6, 2020.

For More Information
RAMP Flyer
All correspondence concerning the program should be addressed to:

Linda Oseso, MPH
RAMP Program Manager
HIV Vaccine Trials Network

Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N., E3-300
Seattle, WA 98109
Office: (206) 667-2175
loseso@fredhutch.org

Implementation Research in HRSA Ryan White Sites: Screening and Treatment for Mental and Substance Use Disorders to Further the National “Ending the HIV Epidemic” (EHE) Goals - Application Due: January 31, 2020

This Funding Opportunity Announcement (FOA) invites applications to enhance screening and treatment for mental and substance use disorders in HRSA Ryan White HIV/AIDS Program funded sites through implementation research, to advance the goals of the National "End the Epidemic" (EHE) initiative. This FOA is intended to support applications seeking to conduct definitive studies on implementation approaches to enhance screening and treatment of substance use or mental health disorders in the HRSA Ryan White HIV/AIDS Program.

LOI Due: December 31, 2019

Application Due: Jan 31, 2020

Applications seeking to conduct definitive studies should consider the companion R01 FOA at RFA-MH-20-520   .

Applications seeking to conduct pilot or feasibility implementation studies should consider the companion R34 FOA at RFA-MH20-521  .

Implementation Research in HRSA Ryan White Sites: Screening and Treatment for Mental and Substance Use Disorders to Further the National “Ending the HIV Epidemic” (EHE) Goals (R01 Clinical Trial Optional) - Expiration Date: February 1, 2020
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA)
  • Purpose: This Funding Opportunity Announcement (FOA) invites applications to enhance screening and treatment for mental and substance use disorders in HRSA Ryan White HIV/AIDS Program funded sites through implementation research, to advance the goals of the National "End the Epidemic" (EHE) initiative. This FOA is intended to support applications seeking to conduct definitive studies on implementation approaches to enhance screening and treatment of substance use or mental health disorders in the HRSA Ryan White HIV/AIDS Program. Applications seeking to conduct pilot or feasibility implementation studies should consider the companion R34 FOA at RFA-MH20-521.
  • Open Date: December 31, 2019
  • Amount of Award: NIH intends to fund an estimate of 4-6 awards for this and the companion FOA , corresponding to a total of $2,000,000, for fiscal year 2020. Future year amounts will depend on annual appropriations.  Direct costs are limited to $500,000 in any single year.
  • Due Date: January 31, 2020
    All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • More Information: NIH
  • Expiration Date: February 1, 2020
     
Food as Medicine: Food Insecurity and HIV-related Comorbidities, Coinfections, and Complications within the Mission of the NIDDK (R01 Clinical Trial Optional) - Expiration Date: March 10, 2020
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Purpose:  This funding opportunity announcement (FOA) seeks US domestic research projects that address how food insecurity effects   HIV comorbidities, coinfections, and complications (CCCs) within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The approaches may address the pathways linking food insecurity and the development or exacerbation of CCCs; or they may evaluate the mechanisms whereby interventions that alleviate food insecurity improve CCCs. These mechanisms could be related to nutritional inadequacies or patient health-related behaviors.
  • Open Date: February 09, 2020
  • Amount of Award: NIDDK intends to commit $2,000,000 in FY 2021 to fund 4-5 awards. Application budgets are limited to $500,000 direct costs per year and need to reflect the actual needs of the proposed project.
  • Due Date: March 9, 2020, by 5:00 PM local time of applicant organization
  • More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-019.html
  • End Date: March 10, 2020
Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01 Clinical Trial Optional) - Expiration Date: May 8, 2020
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • Purpose: HIV+ alcohol users remain at high risk for medication non-adherence and rapid disease progression, medication toxicities, organ failure, and poor viremic control, leading to increased risk of transmission and premature death. Recent advances in technology and biomedical science (e.g., new pharmacological agents, alcohol and inflammation biomarkers, internet and mobile technology) open new opportunities for strengthening the quality of HIV/alcohol-related implementation research through utilization of novel technology and biomarkers. This initiative seeks to advance knowledge on implementation and comparative effectiveness of alcohol-focused interventions among HIV+ individuals. Multiple factors need to be investigated, including potentially important patient and provider characteristics, and the organizational, financial, and structural factors that facilitate or inhibit the delivery of evidence-based services for HIV+ individuals with a range of severity of alcohol use problems. The overall goal is to inform clinical decision-making to implement effective interventions that will improve prevention, care, and outcomes across the continuum of HIV and alcohol problem severity and patterns of alcohol use. This solicitation is divided into two major topics. An application may choose to address one or both. These topics include: 1) comparative effectiveness research focused on understanding factors related to early detection, patient engagement and retention in appropriate alcohol and HIV care, and achieving and maintaining optimal treatment responses in diverse settings, and 2) modeling and testing alternative implementation approaches to improve uptake and scaling-up of effective interventions and reduce HIV disease transmission and progression.
  • Open Date: January 5, 2018
  • Amount of Award: NIH intends to fund an estimate of 4-6 awards, corresponding to a total of $3 million per year, for fiscal year 2018 to 2022.
  • Due Date: Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. 
    Standard AIDS dates apply), by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAS-18-557.html
  • End Date: May 8, 2020
Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional) - Expiration Date: August 4, 2020
  • Participating Organization(s) and Components:  National Institutes of Health (NIH), National Cancer Institute (NCI)
  • Purpose: The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS). These PQs are not intended to represent the full range of NCI's priorities in HIV/AIDS-related cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention.
    Provocative Questions in Cancer with an Underlying HIV Infection involves a set of 6 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.
    This FOA is patterned on, but unrelated to, a series of FOAs for “Research Answers to NCI’s Provocative Questions".
  • Open Date: July 1, 2019
  • Amount of Award: NCI intends to commit $4,000,000 in FY 2021 to fund 6-8 awards.
  • Due Date: August 1, 2019; August 3, 2020, by 5:00 PM local time of applicant organization.
  • More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-032.html
  • End Date: August 4, 2020
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21 Clinical Trial Optional) - Expiration Date: November 13, 2020
  • Participating Organization(s) and Components: National Institutes of Health (NIH), Fogarty International Center (FIC), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Cancer Institute (NCI)
  • Purpose: The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support intervention research on a) novel stigma reduction strategies that link to increase in care-seeking behavior and/or decrease in transmission, b) reducing the impact of stigma on adolescent and/or youth health, c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections, d) reducing the effects of stigma on, and/or by, family members or caregivers of PLWH and e) development of innovative and improved stigma measurement in the context of implementation of a stigma-reduction intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to conduct exploratory studies to determine the feasibility of stigma-reduction interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).
  • Open Date: October 12, 2019
  • Amount of Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $150,000 may be requested in any single year. The budget request must reflect the actual needs of the proposed project.
  • Due Date: November 12, 2019, November 12, 2020  by 5:00 PM local time of applicant organization
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-19-326.html
  • End Date: November 13, 2020
High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional) - Expiration Date: January 8, 2021
NIAID New Innovator PAR for post-doctoral fellows - Expiration Date: October 14, 2021

As part of the NIAID commitment to increase opportunities for post-doctoral fellows, the NIAID New Innovator Award (DP2), PAR-19-296, was published last week. The purpose is to support post-doctoral investigators of exceptional creativity who propose highly innovative bold new research with the potential to produce a major impact on broad, important problems in biomedical research relevant to the mission of NIAID. Applicants approved for funding would have one year to secure an independent, tenure-track (or equivalent) faculty position at an U.S. extramural institution to activate the award.  Through this initiative, NIAID wants to encourage shorter post-doctoral fellowships and provide the opportunity for creative scientists with little to no preliminary data to start their independent careers earlier. NIAID intends to award up to 10 applications per year.
 
Please share this FOA with any talented non-independent postdocs (research and/or clinical doctorate degree, U.S. or non-U.S. citizens), as well as with investigators who may know of appropriate candidates. The next receipt date is November 4, 2019 (once per year); clinical trials are not allowed for this FOA. The DAIDS contact for this PAR is Diane Lawrence.  Her contact info is below:
 
Diane Lawrence, Ph.D.
Program Officer, Pathogenesis and Basic Research Branch
Basic Science Program, Division of AIDS, NIAID
5601 Fishers Lane, Rm 9G22
Bethesda, MD 20892
240-627-3202, lawrencedi@niaid.nih.gov

Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional) - Expiration Date: September 8, 2022
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology, novel tools from data science approaches and m/eHealth, and implementation science research. Data generated through this research will be used to inform and evaluate context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.
  • Open Date: December 7, 2019
  • Amount of Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
  • Due Date:Standard AIDS dates apply.
    All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • More Information: NIH
  • Expiration Date: September 8, 2022